Cover Image
Market Research Report

Latin America Liquid Biopsy Market : Focus on Products and Services, Therapeutic Applications, Clinical Applications, Circulating Biomarkers, 5 Countries Data, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2025

Published by BIS Research Inc. Product code 802030
Published Content info 168 Pages
Delivery time: 1-2 business days
Price
Back to Top
Latin America Liquid Biopsy Market : Focus on Products and Services, Therapeutic Applications, Clinical Applications, Circulating Biomarkers, 5 Countries Data, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2025
Published: March 6, 2019 Content info: 168 Pages
Description

"Latin America Liquid Biopsy Market to Reach $70.9 million by 2025, Reports BIS Research."

Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of molecular cancer biomarkers in the biological fluids. The test principally involves the usage of samples of biological fluids, such as blood, urine, serum, and saliva, and then the analysis of the samples using different techniques, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) to detect the mutations known to cause cancer. The liquid biopsy tests provide a platform to an oncologist for a non-invasive and highly-sensitive tumor profiling of patients. The test provides actionable information about the patients at every critical stage of the treatment cycle. Liquid biopsy tests help in the early detection of tumor-associated mutations in the blood with the help of ctDNA, thus further helping in the betterment of cancer treatment procedure. Growing geriatric population has significantly necessitated the requirement for novel diagnostic procedures based on minimal invasive procedures. Significant degree of research on molecular technologies, cancer biomarkers, and biomarkers presence in body fluids has opened various pathways for the development of a vital non-invasive diagnostic procedure as liquid biopsy.

The purpose of this study is to gain a holistic view of the Latin America liquid biopsy market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the Latin America liquid biopsy market. The market has been segmented into "Product Type", "Circulating Biomarkers", "Clinical Application", "Therapeutic Application", and "Country". The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the Latin America liquid biopsy market, with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report also includes chapters on market dynamics (market drivers, opportunities, and challenges), and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter's Five Forces for a comprehensive understanding of the Latin America liquid biopsy market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple regions, growth of liquid biopsy market in each region for different cancer types, and the key strategies and developments by the prominent liquid biopsy market stake holders.

The answers to the following key questions can be derived from this report:

  • What are the key features of the liquid biopsy technology promoting its incorporation in different clinical applications?
  • What are key advantages of the liquid biopsy technology over tissue biopsy?
  • How did the liquid biopsy market evolve and what is its scope in the future?
  • What are the major market drivers, challenges, and opportunities in the Latin America liquid biopsy market?
  • Which are the leading companies dominating the Latin America liquid biopsy market?
  • Which therapeutic application market would witness massive incorporation of the liquid biopsy technology in the forecast period?
  • Products based on which circulating biomarker are anticipated to witness massive rise in the demand in the forecast period?
  • How would the scope of clinical application of the liquid biopsy technology evolve in the forecast period?
  • What are investors' perceptions about the Latin America liquid biopsy market? Also, who are leading stakeholders of the market holding a significant share in the market's intellectual property?
  • What is the market value of the leading segments and sub-segments of the Latin America liquid biopsy market?
  • How will each segment of the Latin America liquid biopsy market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2025?
  • How will the industry evolve during the forecast period 2019-2025?
  • Which region will contribute to the highest rate of sales of the Latin America liquid biopsy market during the forecast period?

The key players who have been contributing significantly to the Latin America liquid biopsy market are: Biocept, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., MDxHealth Inc., Myriad Genetics Inc., NeoGenomics Laboratories, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Guardant Health, Inc., Menarini Silicon Biosystems, Sysmex Inostics GmbH, MetaCell s.r.o, Contextual Genomics Inc., and Epic Sciences, Inc.

Executive Summary

In the healthcare industry, as technological innovations continue to evolve, they open new avenues for better treatment and prevention approaches for infectious and non-infectious diseases globally. The changes and innovations in healthcare industry have the changed the experiences of the patients, outcomes of chronic diseases, and improved practices of healthcare professionals. Significant degree of research on molecular technologies, cancer biomarkers, and biomarkers presence in body fluids has opened various pathways for the development of a vital non-invasive diagnostic procedure such as liquid biopsy.

Biopsies have been used by the healthcare professionals for the diagnosis and treatment of diseases for about 1,000 years. In cancer cases, biopsies help to reveal the genetic profile of the tumor, which enables prediction of disease progression in the patients and their responses to the therapies. Having established that there is a considerable tumor heterogenicity, obtaining multiple tissue biopsies from the patients seemed difficult, owing to the discomfort caused to the patient during the biopsy process, inherent clinical risks coupled with surgical complications, likely to underestimate the complexity associated with the tumor. Technological advancements in the biopsies have helped to overcome these limitations, enabling proper identification of the genetic and epigenetic aberrations. Liquid biopsy help to provide the genetic landscape of all cancerous lesions present in the patients and also helps track the genomic evolution. Cancer is associated with mutated genes and analysis of these tumor-linked genetic alterations is increasing the diagnosis and treatment purpose. According to the key finding published by the Economist Intelligence Unit report in July 2017, the number of cancer cases in Latin America is projected to rise by 91% and deaths by 106% between 2012 and 2035. Use of biomarkers in the liquid biopsy helps to detect the disease easily, understand disease progression and recurrence, and also helps to indicate if a specific treatment can help to reduce the risk associated with the disease.

The purpose of this study is to gain a holistic view of the Latin America liquid biopsy market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the Latin America liquid biopsy market. The market has been segmented into "Product Type", "Circulating Biomarkers", "Clinical Application", "Therapeutic Application", and "Country". The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

The Latin America liquid biopsy market is anticipated to reach $70.9 million by 2025, witnessing a CAGR of 10.29% in the forecast period 2019-2025. Some of the factors such as growing prominence for rising prevalence of different types of cancer and requirement of novel diagnostic technologies enabling treatment monitoring. Further, the growing prominence of companion diagnostics and substantial investments made in the field of precision medicine are bolstering the growth of the Latin America liquid biopsy market.

In terms of product type, the Latin America liquid biopsy market is dominated by tests and services. The impressive growth in the demand for tests and services, is attributed to the elevated requirement for non-invasive diagnostic services for treatment selection and monitoring. Further, the growing establishment of molecular diagnostics companies providing liquid biopsy tests with short turnaround times is bolstering the growth of the Latin America liquid biopsy tests and services market.

In terms of circulating biomarkers, the Latin America liquid biopsy market is dominated by circulating tumor DNA (ctDNA). The contribution of the products based on circulating tumor DNA (ctDNA) was valued around 40% of the total Latin America liquid biopsy market revenue. However, the market for products based on circulating tumor cells (CTCs) is anticipated to witness the highest CAGR of 11.75% in the forecast period 2018-2025 and outperform the market for products based on ctDNA.

In terms of clinical applications, the Latin America liquid biopsy market is dominated by treatment monitoring. The contribution of treatment monitoring was valued at $11.6 million in 2017, witnessing a CAGR of 9.74% during the forecast period. The growth can be accounted to the increased awareness and adoption of liquid biopsy tests for the early detection and treatment of cancer.

In terms of therapeutic applications, the Latin America liquid biopsy market is dominated by breast cancer treatment. The growth can be accounted to the increased awareness and adoption of liquid biopsy tests for an early detection and treatment of cancer.

In terms of country, Brazil is the leading contributor to the Latin America liquid biopsy market . This can be attributed to growing geriatric population and rising prevalence of different types of cancer have significantly elevated the requirement of novel diagnostic technologies which enable real-time monitoring of cancer treatment in the country.

The key players who have been contributing significantly to the Latin America liquid biopsy market are Biocept, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., MDxHealth Inc., Myriad Genetics Inc., NeoGenomics Laboratories, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Guardant Health, Inc., Menarini Silicon Biosystems, Sysmex Inostics GmbH, MetaCell s.r.o, Contextual Genomics Inc., and Epic Sciences, Inc.

Table of Contents
Product Code: BH121B

Table of Contents

Executive Summary

1. Market Overview

  • 1.1. Historical Trends
  • 1.2. Comparative Analysis of Tissue Biopsy and Liquid Biopsy
  • 1.3. Clinical Applications of Liquid Biopsy
  • 1.4. Trends for Liquid Biopsy
  • 1.5. Latin America Liquid Biopsy Market Scenario

2. Market Dynamics

  • 2.1. Impact Analysis
  • 2.2. Market Drivers
    • 2.2.1. Potential of Liquid Biopsy
    • 2.2.2. Ability to Monitor Clonal Mutations
    • 2.2.3. Growing Prominence of Precision Medicine
  • 2.3. Market Restraints
    • 2.3.1. Uncertain Reimbursement and Regulatory Policies
    • 2.3.2. High Pricing Pressure
    • 2.3.3. Adoption of Traditional Diagnosis Practices
  • 2.4. Market Opportunities
    • 2.4.1. Development of Medication Package Deals
    • 2.4.2. Expansion into Emerging markets
    • 2.4.3. Scope of Liquid Biopsy for Intervention: Diagnosis of Non-Oncology Disorders

3. Competitive Insights

  • 3.1. Market Share Analysis
  • 3.2. Industry Attractiveness
    • 3.2.1. Bargaining Power of Suppliers
    • 3.2.2. Bargaining Power of Buyer
    • 3.2.3. Threat of New Entrants
    • 3.2.4. Threat of Substitute Products
    • 3.2.5. Intensity of Competitive Rivalry

4. Latin America Liquid Biopsy Market (by Product Type)

  • 4.1. Tests/Services
  • 4.2. Kits and Consumables
  • 4.3. Instruments

5. Latin America Liquid Biopsy Market (by Circulating Biomarkers)

  • 5.1. Circulating Tumor DNA (ctDNA)
  • 5.2. Circulating Tumor Cells (CTCs)
  • 5.3. Cell-Free DNA (cfDNA)
  • 5.4. Extracellular Vesicles and Others

6. Latin America Liquid Biopsy Market (by Clinical Applications)

  • 6.1. Treatment Monitoring
  • 6.2. Prognosis and Recurrence Monitoring
  • 6.3. Treatment Selection
  • 6.4. Diagnosis and Screening

7. Latin America Liquid Biopsy Market (by Therapeutic Applications)

  • 7.1. Breast Cancer
  • 7.2. Lung Cancer
  • 7.3. Prostate Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Melanoma Cancer
  • 7.6. Other Types of Cancer
  • 7.7. Non-Oncology Application

8. Latin America Liquid Biopsy Market (by Country)

  • 8.1. Brazil
  • 8.2. Mexico
  • 8.3. Argentina
  • 8.4. Chile
  • 8.5. Colombia
  • 8.6. Rest-of-Latin America

9. Company Profiles

  • 9.1. Overview
  • 9.2. Biocept, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Role of Biocept, Inc. in LATAM Liquid Biopsy Market
    • 9.2.3. Overall Financials
    • 9.2.4. Key Insights about Financial Health of the Company
    • 9.2.5. SWOT Analysis
  • 9.3. Bio-Rad Laboratories, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Role of Bio-Rad Laboratories, Inc. in LATAM Liquid Biopsy Market
    • 9.3.3. Overall Financials
    • 9.3.4. Key Insights about Financial Health of the Company
    • 9.3.5. SWOT Analysis
  • 9.4. Contextual Genomics Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Role of Contextual Genomics Inc. in LATAM Liquid Biopsy Market
    • 9.4.3. SWOT Analysis
  • 9.5. Epic Sciences, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Role of Epic Sciences, Inc. in the LATAM Liquid Biopsy Market
    • 9.5.3. SWOT Analysis
  • 9.6. F. Hoffmann-La Roche AG
    • 9.6.1. Company Overview
    • 9.6.2. Role of F. Hoffmann-La Roche AG in the LATAM Liquid Biopsy Market
    • 9.6.3. Overall Financials
    • 9.6.4. Key Insights about Financial Health of the Company
    • 9.6.5. SWOT Analysis
  • 9.7. Guardant Health, Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Role of Guardant Health, Inc. in LATAM Liquid Biopsy Market
    • 9.7.3. SWOT Analysis
  • 9.8. Illumina, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Role of Illumina, Inc. in the LATAM Liquid Biopsy Market
    • 9.8.3. Overall Financials
    • 9.8.4. Key Insights about Financial Health of the Company
    • 9.8.5. SWOT Analysis
  • 9.9. MDxHealth Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Role of MDxHealth, Inc. in the LATAM Liquid Biopsy Market
    • 9.9.3. Overall Financials
    • 9.9.4. Key Insights on the Financial Health of the Company
    • 9.9.5. SWOT Analysis
  • 9.10 Menarini Silicon Biosystems (Subsidiary of Menarini Group)
    • 9.10.1. Company Overview
    • 9.10.2. Role of Menarini Silicon Biosystems in the LATAM Liquid Biopsy Market
    • 9.10.3. SWOT Analysis
  • 9.11 MetaCell s.r.o
    • 9.11.1. Company Overview
    • 9.11.2. Role of MetaCell s.r.o in LATAM Liquid Biopsy Market
    • 9.11.3. SWOT Analysis
  • 9.12 Myriad Genetics, Inc.
    • 9.12.1. Company Overview
    • 9.12.2. Role of Myriad Genetics, Inc. in LATAM Liquid Biopsy Market
    • 9.12.3. Overall Financials
    • 9.12.4. Key Insights of the Financial Health of the Company
    • 9.12.5. SWOT Analysis
  • 9.13 NeoGenomics Laboratories, Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Role of NeoGenomics Laboratories, Inc. in the LATAM Liquid Biopsy Market
    • 9.13.3. Overall Financials
    • 9.13.4. Key Insights on the Financial Health of the Company
    • 9.13.5. SWOT Analysis
  • 9.14 Qiagen N.V.
    • 9.14.1. Company Overview
    • 9.14.2. Role of Qiagen N.V. in the Liquid Biopsy Market
    • 9.14.3. Overall Financials
    • 9.14.4. Key Insights on the Financial Health of the Company
    • 9.14.5. SWOT Analysis
  • 9.15 Sysmex Inostics GmbH (Subsidiary of Sysmex Corporation)
    • 9.15.1. Company Overview
    • 9.15.2. Role of Sysmex Inostics GmbH in LATAM Liquid Biopsy Market
    • 9.15.3. SWOT Analysis
  • 9.16 Thermo Fisher Scientific Inc.
    • 9.16.1. Company Overview
    • 9.16.2. Role of Thermo Fisher Scientific Inc. in LATAM Liquid Biopsy Market
    • 9.16.3. Financials
    • 9.16.4. Key Insights on the Financial Health of the Company
    • 9.16.5. SWOT Analysis

10. Research Scope and Methodology

  • 10.1. Report Scope

List of Tables

  • Table 1.1: Tissue Biopsy vs. Liquid Biopsy
  • Table 2.1: Impact Analysis
  • Table 2.2: Governmental Initiatives for the Market Growth of Precision Medicine
  • Table 2.3: Incidence of Leading Cancer Types (by Country), 2018 and 2040
  • Table 7.1: Breast Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
  • Table 7.2: Lung Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
  • Table 7.3: Prostate Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
  • Table 7.4: Colorectal Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
  • Table 7.5: Melanoma Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
  • Table 7.6: Ovarian Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
  • Table 7.7: Stomach Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
  • Table 8.1: Healthcare Expenditure (US$ per head) in Latin American Countries, 2015-2017
  • Table 8.2: Brazil: Prevalence of Different Types of Cancer, 2018-2030
  • Table 8.3: Mexico: Prevalence of Different Types of Cancer, 2018-2030
  • Table 8.4: Argentina: Prevalence of Different Types of Cancer, 2018-2030
  • Table 8.5: Chile: Prevalence of Different Types of Cancer, 2018-2030
  • Table 8.6: Colombia: Prevalence of Different Types of Cancer, 2018-2030

List of Figures

  • Figure 1: Few Citations of Liquid Biopsy
  • Figure 2: Latin America Market Drivers and Restraints
  • Figure 3: Latin America Liquid Biopsy Market, 2017-2025
  • Figure 4: Latin America Liquid Biopsy Market (by Product Type), 2017 and 2025
  • Figure 5: Latin America Liquid Biopsy Market (by Circulating Biomarkers), 2017 and 2025
  • Figure 6: Latin America Liquid Biopsy Market (by Clinical Application), 2017-2025
  • Figure 7: Latin America Liquid Biopsy Market (by Therapeutic Application), 2017-2025
  • Figure 8: Latin America Liquid Biopsy Market (by Country), 2017-2025
  • Figure 9: Adoption Rate: Tissue Biopsy vs. Liquid biopsy
  • Figure 1.1: Different Types of Biomarkers in Liquid Biopsy
  • Figure 1.2: Evolution of Liquid Biopsy with Progress in Molecular Technologies and Biomarker Discovery
  • Figure 1.3: Workflow Model of Tissue and Liquid Biopsy
  • Figure 1.4: Clinical Applications of Liquid Biopsy
  • Figure 1.5: Latin America Liquid Biopsy Market, 2017-2025
  • Figure 2.1: Market Dynamics of LATAM Liquid Biopsy Market
  • Figure 3.1: Market Share Analysis: Latin America Liquid Biopsy Market, 2016 and 2017
  • Figure 3.2: Porter's Five Forces Analysis
  • Figure 3.3: Bargaining Power of Suppliers: Overall Impact, 2014-2025
  • Figure 3.4: Bargaining Power of Buyers: Overall Impact, 2014-2025
  • Figure 3.5: Threat of New Entrant: Overall Impact, 2014-2025
  • Figure 3.6: Threat of Substitute Products: Overall Impact, 2014-2025
  • Figure 3.7: Intensity of Competitive Rivalry: Overall Impact, 2014-2025
  • Figure 4.1: Latin America Liquid Biopsy Market (by Circulating Biomarkers)
  • Figure 4.2: Liquid Biopsy Market (by Product Type), 2017-2025
  • Figure 4.3: Latin America Liquid Biopsy Market (by Tests/Services), 2017-2025
  • Figure 4.4: Latin America Liquid Biopsy Market (by Kits and Consumables), 2017-2025
  • Figure 4.5: Latin America Liquid Biopsy Market (by Instruments), 2017-2025
  • Figure 5.1: Different Circulating Biomarkers
  • Figure 5.2: Latin America Liquid Biopsy Market (by Circulating Biomarkers)
  • Figure 5.3: Latin America Liquid Biopsy Market (by Circulating Biomarker), 2017 and 2025
  • Figure 5.4: Latin America Liquid Biopsy Market (by ctDNA), 2017-2025
  • Figure 5.5: CTCs vs. ctDNA Analysis
  • Figure 5.6: Latin America Liquid Biopsy Market (by CTCs), 2017-2025
  • Figure 5.7: Latin America Liquid Biopsy Market (by cfDNA), 2017-2025
  • Figure 5.8: Latin America Liquid Biopsy Market (by Extracellular Vesicles and Others), 2017-2025
  • Figure 6.1: Latin America Liquid Biopsy Market (by Clinical Applications)
  • Figure 6.2: Liquid Biopsy Market (by Clinical Application), 2017-2025
  • Figure 6.3: Latin America Liquid Biopsy Market (by Treatment Monitoring), 2017-2025
  • Figure 6.4: Latin America Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2017-2025
  • Figure 6.5: Latin America Liquid Biopsy Market (by Treatment Selection), 2017-2025
  • Figure 6.6: Latin America Liquid Biopsy Market (by Diagnosis and Screening), 2017-2025
  • Figure 7.1: Latin America Liquid Biopsy Market (by Therapeutic Applications)
  • Figure 7.2: Latin America Liquid Biopsy Market (by Therapeutic Applications), 2017-2025
  • Figure 7.3: Types of Breast Cancer
  • Figure 7.4: Latin America Liquid Biopsy Market (by Breast Cancer), 2017-2025
  • Figure 7.5: Types of Lung Cancer
  • Figure 7.6: Latin America Liquid Biopsy Market (by Lung Cancer), 2017-2025
  • Figure 7.7: Latin America Liquid Biopsy Market (by Prostate Cancer), 2017-2025
  • Figure 7.8: Latin America Liquid Biopsy Market (by Colorectal Cancer), 2017-2025
  • Figure 7.9: Latin America Liquid Biopsy Market (by Melanoma Cancer), 2017-2025
  • Figure 7.10: Latin America Liquid Biopsy Market (by Other Types of Cancer), 2017-2025
  • Figure 7.11: Latin America Liquid Biopsy Market (by Non-Oncology), 2017-2025
  • Figure 8.1: Latin America Liquid Biopsy Market, 2017-2025
  • Figure 8.2: Latin America Liquid Biopsy Market (by Country), 2017-2025
  • Figure 8.3: Brazil Liquid Biopsy Market, 2017-2025
  • Figure 8.4: Brazil Liquid Biopsy Market (by Therapeutic Application), 2017-2025
  • Figure 8.5: Mexico Liquid Biopsy Market, 2017-2025
  • Figure 8.6: Mexico: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
  • Figure 8.7: Argentina Liquid Biopsy Market, 2017-2025
  • Figure 8.8: Argentina: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
  • Figure 8.9: Chile Liquid Biopsy Market, 2017-2025
  • Figure 8.10: Chile: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
  • Figure 8.11: Colombia Liquid Biopsy Market, 2017-2025
  • Figure 8.12: Colombia: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
  • Figure 8.13: Rest-of-Latin America Liquid Biopsy Market, 2017-2025
  • Figure 9.1: Shares of Key Company Profiles
  • Figure 9.2: Product Offerings
  • Figure 9.3: Biocept, Inc.: Overall Financials, 2015-2017
  • Figure 9.4: Biocept, Inc.: R&D Expense, 2015-2017
  • Figure 9.5: Biocept, Inc.: SWOT Analysis
  • Figure 9.6: Bio-Rad Laboratories, Inc.: Product Offerings
  • Figure 9.7: Bio-Rad laboratories, Inc.: Overall Financials, 2015-2017
  • Figure 9.8: Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 9.9: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017
  • Figure 9.10: Bio-Rad Laboratories, Inc.: R&D Expense, 2015-2017
  • Figure 9.11: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 9.12: Contextual Genomics Inc.: SWOT Analysis
  • Figure 9.13: Epic Sciences, Inc.: Product Offerings
  • Figure 9.14: Epic Sciences, Inc.: SWOT Analysis
  • Figure 9.15: F. Hoffmann-La Roche AG: Product Offerings
  • Figure 9.16: F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
  • Figure 9.17: F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017
  • Figure 9.18: F. Hoffmann-La Roche Ltd.: Revenue (by Diagnostics Sub-division), 2015-2017
  • Figure 9.19: F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
  • Figure 9.20: F. Hoffmann-La Roche AG: R&D Expense, 2015-2017
  • Figure 9.21: F. Hoffmann-La Roche AG: SWOT Analysis
  • Figure 9.22: Guardant Health, Inc.: Product Offerings
  • Figure 9.23: Guardant Health, Inc.: SWOT Analysis
  • Figure 9.24: Illumina, Inc.: Product Offerings
  • Figure 9.25: Illumina, Inc.: Overall Financials, 2015-2017
  • Figure 9.26: Illumina, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 9.27: Illumina, Inc.: Revenue (by Region), 2015-2017
  • Figure 9.28: Illumina, Inc.: R&D Expense, 2015-2017
  • Figure 9.29: Illumina, Inc.: SWOT Analysis
  • Figure 9.30: MDxHealth, Inc.: Product Offerings
  • Figure 9.31: MDxHealth, Inc.: Overall Financials, 2015-2017
  • Figure 9.32: MDxHealth, Inc.: R&D Expanse, 2015-2017
  • Figure 9.33: MDxHealth, Inc.: SWOT Analysis
  • Figure 9.34: Menarini Silicon Biosystems, Inc.: Product Offerings
  • Figure 9.35: Menarini Silicon Biosystems, Inc.: SWOT Analysis
  • Figure 9.36: Metacell s.r.o: SWOT Analysis
  • Figure 9.37: Myriad Genetics, Inc.: Product Offerings
  • Figure 9.38: Myriad Genetics, Inc.: Overall Financials, 2015-2017
  • Figure 9.39: Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 9.40: Myriad Genetics, Inc.: Revenue (by Region), 2015-2017
  • Figure 9.41: Myriad Genetics, Inc.: R&D Expense, 2015-2017
  • Figure 9.42: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 9.43: NeoGenomics Laboratories, Inc.: Product Offerings
  • Figure 9.44: NeoGenomics Laboratories, Inc.: Overall Financials, 2015-2017
  • Figure 9.45: NeoGenomics Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 9.46: NeoGenomics Laboratories, Inc.: R&D Expense, 2015-2017
  • Figure 9.47: NeoGenomics Laboratories, Inc.: SWOT Analysis
  • Figure 9.48: Qiagen N.V.: Product Offerings
  • Figure 9.49: Qiagen N.V.: Overall Financials, 2015-2017
  • Figure 9.50: Qiagen N.V.: Revenue (by Business Segment), 2015-2017
  • Figure 9.51: Qiagen N.V.: Revenue (by Region), 2015-2017
  • Figure 9.52: Qiagen N.V.: R&D Expense, 2015-2017
  • Figure 9.53: Qiagen N.V.: SWOT Analysis
  • Figure 9.54: Sysmex Inostics GmbH: Product Offerings
  • Figure 9.55: Sysmex Inostics GmbH: SWOT Analysis
  • Figure 9.56: Thermo Fisher Scientific Inc.: Product Offerings
  • Figure 9.57: Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
  • Figure 9.58: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 9.59: Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
  • Figure 9.60: Thermo Fisher Scientific Inc.: R&D Expense, 2015-2017
  • Figure 9.61: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 10.1: Latin America Liquid Biopsy: Market Segmentation
  • Figure 10.2: Latin America Liquid Biopsy Market Segmentation
  • Figure 10.3: Primary Research
  • Figure 10.4: Secondary Research
  • Figure 10.5: Data Triangulation
  • Figure 10.6: Top-down Approach (Segment-wise Analysis)
  • Figure 10.7: Bottom-up Approach (Segment-wise Analysis)
  • Figure 10.8: Assumptions and Limitations
  • Figure 10.9: Considered Factors for Data Prediction and Modelling
Back to Top